TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02094079

Intervention type: OTHER
Intervention: biomedical outcomes
Description: Evaluation of abnormal blodtests (evaluating thyroid function) from predefined control program
Study: NCT04902950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The Tranexamic acid soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The saline soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient.
Study: NCT04695587

Intervention type: DIAGNOSTIC_TEST
Intervention: ECHO
Description: ECHO in subacute phase and 12 months after the acute episode

Intervention type: DIAGNOSTIC_TEST
Intervention: 24hour ECG
Description: 24hour ECG in subacute phase and 12 months after the acute episode

Intervention type: DIAGNOSTIC_TEST
Intervention: CMR
Description: CMR in 12 months after the acute episode
Study: NCT03929016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNDI-0690
Description: capsules of 10, 100 and 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNDI-0690
Description: capsules of 10, 100 and 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNDI-0690
Description: capsules of 10, 100 and 200 mg
Study: NCT00955383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK2190915
Description: GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
Study: NCT02365532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-6615
Description: GS-6615 tablets administered orally
Study: NCT03929016

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of DNDI-0690
Description: capsules of matching placebo
Study: NCT02365532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GS-6615
Description: Placebo to match GS-6615 tablets administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match GS-6615
Description: Placebo to match GS-6615 tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match dofetilide
Description: Placebo to match dofetilide capsules administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match dofetilide
Description: Placebo to match dofetilide capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dofetilide
Description: Dofetilide 500 μg capsules administered orally according to the current prescribing information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dofetilide
Description: Dofetilide 500 μg capsules administered orally according to the current prescribing information
Study: NCT04397055

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cottonseed Oil
Description: Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Cottonseed Oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive Oil
Description: Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Olive Oil
Study: NCT00955383

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT03929016

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of DNDI-0690
Description: capsules of matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of DNDI-0690
Description: capsules of matching placebo
Study: NCT04655586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rNAPc2
Description: two dose levels of rNAPc2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rNAPc2
Description: two dose levels of rNAPc2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: standard of care heparin per institution (therapeutic or prophylactic regimen)
Study: NCT01011062

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia
Description: Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia
Description: Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Acute administration of losartan 200mg total prior to clamp

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Infusion of Saline as a volume control intervention
Study: NCT04469530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus is given at a dose of 2 mg/m2 once daily. The amber oral dose syringe should be used to withdraw the prescribed amount of sirolimus oral solution from the bottle. The solution can be drunk or administered at once to assure delivery of all of the medication. It is safe for administration through a nasogastric or G-tube. For tablets, the tablet should not be crushed, split, or otherwise altered. As with the liquid dosing form, the tablets should be given within two hours each day and should be at consistent intervals with regard to meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A synthetic antineoplastic drug chemically related to the nitrogen mustards. The drug is administered orally daily, in the formulation appropriate for age.~The solution should be diluted in 20-30 ml of appropriate liquid before administration through nasogastric (NG) tube or gastrostomy (G) tube, with adequate flushing after administration to prevent obstruction of the feeding tube.
Study: NCT00924638

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reveal® XT Insertable Cardiac Monitor
Description: The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.
Study: NCT00757419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: capsules, oral, single or twice daily dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To match dosing of AZD3355
Study: NCT02988258

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CMV-TCR transduced donor-derived T cells
Description: Dose escalation

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CMV-TCR transduced donor-derived T cells
Description: Dose escalation

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CMV-TCR transduced donor-derived T cells
Description: Dose escalation
Study: NCT01269658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin ophthalmic solution, 1%
Description: 1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
Study: NCT02928744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD
Description: Plethysmography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD
Description: Forced oscillations
Study: NCT02047305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: Patients with a histopathological diagnosis of moderate-grade intra-epithelial neoplasia (MGIN), high-grade intra-epithelial neoplasia (HGIN) and/or early flat-type SCCA of the esophagus, are treated with radiofrequency ablation, with repeat endoscopy and follow-up treatment at 3 month intervals.
Study: NCT03392051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 681257
Description: Xmg dose administered as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 75mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 75mg tablet administered orally
Study: NCT05768334

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lubiprostone 24Mcg Oral twice daily
Description: The patients will be randomized (closed envelopes) into one of two groups:~1. Fifty patients will receive lubiprostone 24 mcg (microgram) twice daily.~2. Fifty patients will receive placebo twice daily (control group). All patients will be followed for 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone 24Mcg Oral twice daily
Description: The patients will be randomized (closed envelopes) into one of two groups:~1. Fifty patients will receive lubiprostone 24 mcg (microgram) twice daily.~2. Fifty patients will receive placebo twice daily (control group). All patients will be followed for 48 weeks.
Study: NCT04658225

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 0.12% chlorhexidine
Description: the patients were randomly allocated into two groups of 15 individuals to rinse with antimicrobials twice a day for a period of four weeks. Group A, received 0.12% chlorhexidine antimicrobian in a vial previously identified as solution 1 and group B, received saline solution identified as solution 2.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 0.12% chlorhexidine
Description: the patients were randomly allocated into two groups of 15 individuals to rinse with antimicrobials twice a day for a period of four weeks. Group A, received 0.12% chlorhexidine antimicrobian in a vial previously identified as solution 1 and group B, received saline solution identified as solution 2.
Study: NCT01291095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CISPLATIN
Description: IN CRT ARM:RADIATION ONE FRACTION PER DAY, ON FIVE CONSECUTIVE DAYS FROM MONDAY TO FRIDAY ALONG WITH INTRAVENOUS CISPLATIN 40mg/m2 WEEKLY FOR SEVEN DOSES.~IN AFRT ARM: PATIENTS WILL NOT RECEIVE ANY CHEMOTHERAPY WITH CISPLATIN

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EXTERNAL BEAM RADIOTHERAPY
Description: Patients assigned to CRT arm will be given radiation one fraction per day, on five consecutive days from Monday to Friday along with intravenous cisplatin 40 mg/m2 weekly for seven doses (a minimum of 5weekly chemotherapy). Patients assigned to AFRT arm will undergo radiation similarly one fraction per day and then the sixth fraction will be given on another day (Saturday) or as an extra fraction on one of the first five days, but always allowing at least a 6-hour interval between fractions on same day. If any unintended interruption of the treatment occurs, this missing treatment will be given as soon as possible, preferably within a week, but not allowing more than 14 Gy to be given during any 7-day period.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: EXTERNAL BEAM RADIOTHERAPY
Description: Patients assigned to CRT arm will be given radiation one fraction per day, on five consecutive days from Monday to Friday along with intravenous cisplatin 40 mg/m2 weekly for seven doses (a minimum of 5weekly chemotherapy). Patients assigned to AFRT arm will undergo radiation similarly one fraction per day and then the sixth fraction will be given on another day (Saturday) or as an extra fraction on one of the first five days, but always allowing at least a 6-hour interval between fractions on same day. If any unintended interruption of the treatment occurs, this missing treatment will be given as soon as possible, preferably within a week, but not allowing more than 14 Gy to be given during any 7-day period.
Study: NCT02966782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Powder for injection, subcutaneously or intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Powder for injection, subcutaneously or intravenous
Study: NCT02881541

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced support

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual care
Study: NCT02075645

Intervention type: OTHER
Group type: OTHER
Intervention: Team training course
Description: A 1-day simulation-based team-training course. There will be 4 simulated resuscitation events. Simulation #1 will be the pre-course team performance and simulation #4 will be the post-course performance.
Study: NCT04178122

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Result disclosure
Description: Disclosure of clinically confirmed, medically actionable genetic testing results and post-test genetic counseling session.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Result disclosure
Description: Disclosure of clinically confirmed, medically actionable genetic testing results and post-test genetic counseling session.
Study: NCT03822130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arterial catheter infusion chemotherapy
Description: Arterial catheter infusion chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arterial catheter infusion chemotherapy
Description: Arterial catheter infusion chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Arterial catheter infusion Sodium Bicarbonate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Systemic Chemotherapy
Description: Systemic Chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Chemotherapy
Description: Oral Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Chemotherapy
Description: Oral Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Chemotherapy
Description: Oral Chemotherapy
Study: NCT03366792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artemis™ software system
Description: Computerized targeting of mpMRI lesions. The computerized co-registration will then be performed by software within the Artemis™ system and will fuse the MR imaging with real-time ultrasound imaging.
Study: NCT04469530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: A semisynthetic derivative of podophyllotoxin which functions as mitotic inhibitor but does not interfere with microtubular assembly. The drug is administered orally daily, in the formulation appropriate for age.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: The drug is administered orally daily, in the formulation appropriate for age.The solution is safe for administration through a nasogastric or G-tube.
Study: NCT03918031

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PFI for Smoking & Distress Tolerance
Description: Personalized Feedback Intervention for smoking and distress tolerance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PFI for Smoking Only
Description: Personalized Feedback Intervention for smoking only (no distress tolerance component)
Study: NCT03209453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: family work shop
Description: Children with developmental delays, under regular rehabilitation programs, participate 6 sessions of family work shop The family work shop had 6 families in one course, 2 hours per week, for a total of 6 weeks.
Study: NCT04171427

Intervention type: OTHER
Group type: OTHER
Intervention: Lithium liposome
Description: Cosmetic product

Intervention type: OTHER
Group type: OTHER
Intervention: Lithium liposome
Description: Cosmetic product

Intervention type: OTHER
Group type: OTHER
Intervention: Lithium liposome
Description: Cosmetic product

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Cosmetic product vehicle

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Cosmetic product vehicle

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Cosmetic product vehicle
Study: NCT03304496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 100 MCG/ML Injectable Solution
Description: Previously described.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Previously described.
Study: NCT04064567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP-LINK
Description: CHW will assist with healthcare and social service navigation and will utilize adherence counseling techniques. As per the model our intervention is based upon (the national Transitions Clinic Network \[TCN\]), our CHW has a history of incarceration. Participants randomized to the intervention group, the CHW will assist individuals with employment, housing (if needed), referrals to mental health or substance use treatment, keeping track of medical appointments and medication adherence.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care
Description: Participants will receive education about PrEP and referral to a community PrEP provider which exceeds the standards of care these individuals would otherwise receive.
Study: NCT00393640

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early and regular breast milk expression
Description: Breast pump given to be used on regular intervals

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early and regular breast milk expression
Description: Breast pump given to be used on regular intervals
Study: NCT04626466

Intervention type: OTHER
Intervention: Biological investigations
Description: (complete blood count, platelet count, renal function evaluation)
Study: NCT03465423

Intervention type: PROCEDURE
Intervention: Not applicable (measuring subject's effect site concentration of propofol during the induction of general anesthesia)
Description: The patients of two cohort group will undergo general anesthesia in the same way and therefore there is no intervention in this study.
Study: NCT01670227

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PARENTCORPS
Description: ParentCorps is a culturally-informed, universal intervention (for all children enrolled in Pre-K within an elementary school) designed to promote positive behavioral supports for children at home and in the classroom. ParentCorps includes two complementary components: 1) parent and child group intervention (13 2-hour sessions after school) for Pre-K students and their families; 2) professional development and individual consultation for early childhood teachers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PARENTCORPS
Description: ParentCorps is a culturally-informed, universal intervention (for all children enrolled in Pre-K within an elementary school) designed to promote positive behavioral supports for children at home and in the classroom. ParentCorps includes two complementary components: 1) parent and child group intervention (13 2-hour sessions after school) for Pre-K students and their families; 2) professional development and individual consultation for early childhood teachers.
Study: NCT01307280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RCT1
Description: the bookHEALTH manual and eHEALTH tools, the basic Internet component of the intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RCT2
Description: bookHEALTH and an interactive version of eHEALTH that provided tailored computerized feedback whenever participants submitted weekly assessments

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RCT3
Description: bookHEALTH, the interactive version of eHEALTH, and telephonic coaching support provided by trained health lifestyle coaches every 2 weeks alternating between a telephone call (typically 15 to 20 minutes) and a personalized e-mail. The coaches used motivational interviewing, helped participants solve problems, and reinforced their successes.
Study: NCT02166151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizimab
Description: Omalizimab 150 mg S.C. once a month for consecutive 3 months
Study: NCT03877263

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Endocervical swab for detection of STI
Description: After we collect the samples, they will be evaluated using the Hologic APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae assays.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Endocervical swab for detection of STI
Description: After we collect the samples, they will be evaluated using the Hologic APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae assays.
Study: NCT06259630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participant receives oral dose of nicotine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participant receives oral dose of nicotine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Participant receives oral dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Participant receives oral dose of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Participant receives oral dose of placebo